About R&Q R&Q is a non-life global specialty insurance company operating two core, highly complementary, businesses: Program Management and Legacy Insurance. Both these businesses are leaders in markets with high barriers to entry and significant secular growth opportunities. Legacy Insurance generates profits and capital extractions from expert management of legacy non-life insurance portfolios. Program Management generates commission income from its licensed (and rated) carriers in the US, EU and the UK, writing niche and profitable program business, largely on behalf of highly rated reinsurers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost
Wed, 23rd Dec 2020 19:50
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Polarean Imaging PLC - medical imaging products developer - Says US Food & Drug Administration approves company s new drug application. FDA acceptance for the filing of Polarean s NDA represents another important step forward for the Company s platform. If approved, Polarean s drug-device technology could provide a new diagnostic option for patients with pulmonary disease, Chief Executive Officer Richard Hullihen says. Polarean adds that Chief Operating Officer Ken West plans to retire as employee of company but to stay involved as a consultant before transitioning to non-executive role.